AMITABHA MAZUMDER
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- DOWNEY, CA
- NPI
- 1881682318
- Received
- $206,998 in 1,107 records, 2019 to 2025
- As principal investigator
- $3,019,597 of research payments to others in 137 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 163 | $6,517 |
| 2024 | General payment | 204 | $5,997 |
| 2023 | General payment | 180 | $19,837 |
| 2022 | General payment | 152 | $22,415 |
| 2021 | General payment | 123 | $31,614 |
| 2020 | General payment | 120 | $35,719 |
| 2019 | General payment | 165 | $84,897 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 46 | $107,065 |
| Honoraria | 17 | $34,175 |
| Consulting Fee | 15 | $30,320 |
| Food and Beverage | 987 | $23,288 |
| Travel and Lodging | 25 | $10,811 |
| Long term medical supply or device loan | 13 | $1,279 |
| Education | 4 | $58 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-07 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-10-31 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-30 | Iovance Biotherapeutics, Inc. | $18 | Food and Beverage | Cash or cash equivalent | Amtagvi Drug, Oncology | 2025 | |
| 2025-10-29 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-10-21 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-21 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-17 | TAIHO ONCOLOGY, INC. | $32 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2025 | |
| 2025-10-17 | ADC THERAPEUTICS AMERICA, INC. | $25 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-10-14 | Gilead Sciences, Inc. | $26 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-10-13 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-10-10 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-10-10 | Karyopharm Therapeutics Inc. | $25 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $13 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-10-08 | ARRAY BIOPHARMA INC | $14 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-10-07 | ARRAY BIOPHARMA INC | $9 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-10-06 | AstraZeneca Pharmaceuticals LP | $31 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-06 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-10-03 | TerSera Therapeutics LLC | $35 | Food and Beverage | In-kind items and services | Zoladex Drug, Oncology | 2025 | |
| 2025-10-02 | Daiichi Sankyo Inc. | $28 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Regeneron Healthcare Solutions, Inc. | $31 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-09-29 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-09-25 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-23 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-20 | Genmab U.S., Inc. | $26 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-09-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-09-15 | Agios Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-09-12 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2025 | |
| 2025-09-09 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-08 | ARRAY BIOPHARMA INC | $20 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-09-05 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | Celgene Corporation | $21 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-02 | Stemline Therapeutics Inc. | $25 | Food and Beverage | In-kind items and services | ELZONRIS Drug, Oncology | 2025 | |
| 2025-08-29 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-08-28 | GENZYME CORPORATION | $47 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-08-27 | Janssen Biotech, Inc. | $37 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-08-26 | Janssen Biotech, Inc. | $18 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2025-08-25 | Janssen Biotech, Inc. | $43 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-08-25 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-08-20 | Incyte Corporation | $27 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-08-19 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-08-19 | Amgen Inc. | $26 | Food and Beverage | In-kind items and services | BLINCYTO Biological, Oncology | 2025 | |
| 2025-08-15 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-08-12 | E.R. Squibb & Sons, L.L.C. | $26 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2025 | |
| 2025-08-11 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-11 | RECORDATI_RARE_DISEASES_INC. | $24 | Food and Beverage | In-kind items and services | ENJAYMO Drug, HEMATOLOGY | 2025 | |
| 2025-08-08 | Astellas Pharma US Inc | $26 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-08-07 | Janssen Biotech, Inc. | $44 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-08-07 | AstraZeneca Pharmaceuticals LP | $10 | Food and Beverage (3 payments) | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-08-05 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-08-04 | AstraZeneca Pharmaceuticals LP | $34 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2025 | |
| 2025-08-01 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-07-31 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-07-29 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-07-24 | Syndax Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-22 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-07-15 | Legend Biotech USA Inc. | $15 | Food and Beverage | In-kind items and services | CARVYKTI Biological, Oncology | 2025 | |
| 2025-07-14 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-07-11 | Gilead Sciences, Inc. | $31 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-07-10 | Takeda Pharmaceuticals U.S.A., Inc. | $28 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-07-08 | Agios Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2025 | |
| 2025-07-03 | Alexion Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-07-01 | TAIHO ONCOLOGY, INC. | $31 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2025 | |
| 2025-06-26 | Karyopharm Therapeutics Inc. | $28 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-06-24 | Janssen Biotech, Inc. | $31 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-06-20 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-06-11 | E.R. Squibb & Sons, L.L.C. | $2,485 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-06 | Lilly USA, LLC | $31 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-06-05 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-06-03 | E.R. Squibb & Sons, L.L.C. | $14 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-06-02 | Karyopharm Therapeutics Inc. | $17 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-05-30 | Genmab U.S., Inc. | $26 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-05-29 | GlaxoSmithKline, LLC. | $28 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-05-27 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | ELAHERE Drug, ONCOLOGY | 2025 | |
| 2025-05-23 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2025-05-22 | ADC THERAPEUTICS AMERICA, INC. | $24 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-05-20 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-05-20 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-05-16 | Blueprint Medicines Corporation | $15 | Food and Beverage | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2025 | |
| 2025-05-16 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-05-16 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-05-16 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-05-15 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | TAGRISSO Drug, Oncology | 2025 | |
| 2025-05-13 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-05-09 | ARRAY BIOPHARMA INC | $21 | Food and Beverage | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2025 | |
| 2025-05-08 | Gilead Sciences, Inc. | $24 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-05-06 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2025 | |
| 2025-05-06 | E.R. Squibb & Sons, L.L.C. | $2 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2025 | |
| 2025-05-05 | Exelixis Inc. | $33 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-05-02 | Stemline Therapeutics Inc. | $23 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-05-01 | Janssen Biotech, Inc. | $26 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-04-29 | ARRAY BIOPHARMA INC | $28 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-04-28 | Celgene Corporation | $27 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-04-28 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-04-24 | Novartis Pharmaceuticals Corporation | $83 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-04-24 | PharmaEssentia USA Corporation | $17 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-04-22 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | VPRIV Biological, GENETIC DISEASE | 2025 | |
| 2025-04-18 | GENZYME CORPORATION | $44 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-04-17 | Deciphera Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-04-16 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-04-15 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-04-14 | EMD Serono, Inc. | $27 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-10 | Genentech USA, Inc. | $27 | Food and Beverage | In-kind items and services | Polivy Biological, BioOncology | 2025 | |
| 2025-04-10 | Merck Sharp & Dohme LLC | $25 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-04-08 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-04-07 | Daiichi Sankyo Inc. | $25 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-04-07 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-04-07 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-04-04 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-04-03 | GENZYME CORPORATION | $43 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-03-31 | Astellas Pharma US Inc | $21 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-03-27 | Karyopharm Therapeutics Inc. | $18 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-03-26 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-03-25 | Eisai Inc. | $17 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2025 | |
| 2025-03-24 | Stemline Therapeutics Inc. | $38 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-03-20 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-18 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-03-17 | PharmaEssentia USA Corporation | $28 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-03-14 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-03-14 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2025 | |
| 2025-03-12 | Takeda Pharmaceuticals U.S.A., Inc. | $32 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-03-11 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2025 | |
| 2025-03-07 | TAIHO ONCOLOGY, INC. | $30 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2025 | |
| 2025-03-07 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-02-28 | Daiichi Sankyo Inc. | $17 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-02-27 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-02-21 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-02-20 | ADC THERAPEUTICS AMERICA, INC. | $17 | Food and Beverage | Cash or cash equivalent | ZYNLONTA Drug, ONCOLOGY | 2025 | |
| 2025-02-18 | ARRAY BIOPHARMA INC | $24 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-02-18 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-02-17 | Tempus AI, Inc | $26 | Food and Beverage | In-kind items and services | XT CDX Device, ONCOLOGY | 2025 | |
| 2025-02-14 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-02-13 | Takeda Pharmaceuticals U.S.A., Inc. | $26 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2025 | |
| 2025-02-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2025 | |
| 2025-02-10 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-02-10 | AstraZeneca Pharmaceuticals LP | $6 | Education | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-02-07 | EMD Serono, Inc. | $29 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-02-06 | Geron Corporation | $33 | Food and Beverage | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-02-05 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-02-04 | Exelixis Inc. | $18 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-01-31 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | 2025 | |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-01-28 | PharmaEssentia USA Corporation | $13 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-01-27 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-01-24 | Blueprint Medicines Corporation | $38 | Food and Beverage | Cash or cash equivalent | AYVAKIT Drug, Oncology / Rare Diseases | 2025 | |
| 2025-01-24 | Janssen Biotech, Inc. | $26 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2025 | |
| 2025-01-24 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-01-23 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-01-21 | Syndax Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-17 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-01-15 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-01-14 | Gilead Sciences, Inc. | $26 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-01-07 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-01-07 | Janssen Biotech, Inc. | $1 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-01-06 | Ipsen Biopharmaceuticals, Inc | $21 | Food and Beverage | In-kind items and services | Onivyde Drug, Oncology | 2025 | |
| 2025-01-06 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-01-03 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-01-03 | BeiGene USA, Inc. | $21 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-01-02 | Janssen Biotech, Inc. | $16 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2024-12-31 | Regeneron Healthcare Solutions, Inc. | $36 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-12-27 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2024 | |
| 2024-12-24 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2024 | |
| 2024-12-23 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2024 | |
| 2024-12-19 | Celgene Corporation | $18 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2024 | |
| 2024-12-19 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-12-19 | Janssen Biotech, Inc. | $1 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2024 | |
| 2024-12-17 | Agios Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | $33 | Food and Beverage | In-kind items and services | FRUZAQLA Drug, ONCOLOGY | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $33 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2024 | |
| 2024-12-12 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2024 | |
| 2024-12-12 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-12-10 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-12-10 | TerSera Therapeutics LLC | $36 | Food and Beverage | In-kind items and services | Xermelo Drug, Oncology | 2024 | |
| 2024-12-07 | TAIHO ONCOLOGY, INC. | $29 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2024 | |
| 2024-12-05 | Novocure Inc. | $21 | Food and Beverage | Cash or cash equivalent | Optune Lua (NovoTTF-200T) Device, Oncology | 2024 | |
| 2024-12-03 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-11-26 | SOBI, INC | $25 | Food and Beverage | In-kind items and services | SYNAGIS Drug, IMMUNOLOGY | 2024 | |
| 2024-11-26 | SOBI, INC | $3 | Food and Beverage | In-kind items and services | SYNAGIS Drug, IMMUNOLOGY | 2024 | |
| 2024-11-25 | Takeda Pharmaceuticals U.S.A., Inc. | $32 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2024 | |
| 2024-11-25 | SOBI, INC | $0 | Food and Beverage | In-kind items and services | SYNAGIS Drug, IMMUNOLOGY | 2024 | |
| 2024-11-21 | Novartis Pharmaceuticals Corporation | $31 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-11-19 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2024 | |
| 2024-11-18 | Agios Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | PYRUKYND Drug, Genetically Defined Disease | 2024 | |
| 2024-11-14 | Novartis Pharmaceuticals Corporation | $99 | Long term medical supply or device loan | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-11-14 | Astellas Pharma US Inc | $20 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2024 | |
| 2024-11-12 | ADC THERAPEUTICS AMERICA, INC. | $27 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-11 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2024 | |
| 2024-11-11 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2024 | |
| 2024-11-08 | TAIHO ONCOLOGY, INC. | $25 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2024 | |
| 2024-11-07 | Celgene Corporation | $17 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2024 | |
| 2024-11-07 | Celgene Corporation | $3 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2024 | |
| 2024-11-05 | SUN PHARMACEUTICAL INDUSTRIES INC. | $28 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2024 | |
| 2024-10-31 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-10-29 | Celgene Corporation | $24 | Food and Beverage | Cash or cash equivalent | OPDUALAG Drug, Oncology | 2024 | |
| 2024-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | GILOTRIF Drug, ONCOLOGY | 2024 | |
| 2024-10-17 | E.R. Squibb & Sons, L.L.C. | $593 | Consulting Fee | Cash or cash equivalent | 2024 |
The latest 200 records of 1,107.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | Janssen Research & Development, LLC | HELIOS CR INC | $402 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | HELIOS CR INC | $234 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-12-15 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $2,288 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | HELIOS CR INC | $1,706 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | HELIOS CR INC | $72 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | HELIOS CR INC | $85 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | Helios Clinical Research | $9,785 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (Ibe | 2025 |
| 2025-11-07 | Janssen Research & Development, LLC | HELIOS CR INC | $2,901 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-11-03 | E.R. Squibb & Sons, L.L.C. | Helios Clinical Research | $60,516 | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMET | 2025 |
| 2025-10-24 | Janssen Research & Development, LLC | HELIOS CR INC | $2,159 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-10-24 | Janssen Research & Development, LLC | HELIOS CR INC | $63 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-10-24 | Janssen Research & Development, LLC | HELIOS CR INC | $12,137 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-10-20 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $3,084 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-10-14 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $418 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-10-06 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $3,459 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-09-26 | Celgene Corporation | Helios Clinical Research | $11,920 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (Ibe | 2025 |
| 2025-09-22 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $150 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-09-15 | Janssen Research & Development, LLC | HELIOS CR INC | $75 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-09-15 | Janssen Research & Development, LLC | HELIOS CR INC | $72 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-09-01 | Janssen Research & Development, LLC | HELIOS CR INC | $1,775 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-08-19 | Ionis Pharmaceuticals, Inc. | TOI CLINICAL RESEARCH | $5,599 | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacod | 2025 |
| 2025-08-04 | Janssen Research & Development, LLC | HELIOS CR INC | $217 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-08-04 | Janssen Research & Development, LLC | HELIOS CR INC | $217 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-08-04 | Janssen Research & Development, LLC | HELIOS CR INC | $217 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-08-04 | Janssen Research & Development, LLC | HELIOS CR INC | $12,137 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | HELIOS CR INC | $64 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | HELIOS CR INC | $76 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | HELIOS CR INC | $90 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-07-09 | Celgene Corporation | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $31,147 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (Ibe | 2025 |
| 2025-07-04 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $1,706 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-07-02 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $190 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-06-16 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $2,512 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-05-26 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $1,069 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-05-16 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $33 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-05-16 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $26 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-05-16 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $26 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-05-12 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $173 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-05-12 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $2,512 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-05-05 | Celgene Corporation | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $89,372 | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMET | 2025 |
| 2025-05-05 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $4,603 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-28 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $366 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-04-22 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $28 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-22 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $12,137 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-21 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $95 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-04-07 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $66 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-07 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $57 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-07 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $33 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-07 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $24 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-07 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $67 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-04-02 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $2,512 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-03-31 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $8,141 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-03-14 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $79 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-03-10 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $3,871 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-03-06 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $28 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-03-06 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $35 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-02-24 | GENZYME CORPORATION | TOI CLINICAL RESEARCH | $106 | POC - Warm autoimmune hemolytic anemia | 2025 |
| 2025-01-27 | E.R. Squibb & Sons, L.L.C. | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $5,123 | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMET | 2025 |
| 2025-01-27 | E.R. Squibb & Sons, L.L.C. | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $46,213 | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMET | 2025 |
| 2025-01-23 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $64 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-01-23 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $53 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-01-23 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $58 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-01-23 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $60 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $308,368 | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2025 |
| 2024-12-26 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $59 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-12-26 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $12,137 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-12-26 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $59 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-12-16 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $2,932 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-12-16 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $83 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-12-16 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $183 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $60 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-11-28 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $59 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-11-11 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $78 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-11-04 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $59 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-11-04 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $11,664 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-11-04 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $1,998 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-11-04 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $2,698 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $57 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $54 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $59 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $60 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-10-28 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH LLC | $59 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-10-02 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $1,349 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-10-02 | SANOFI US SERVICES INC. | CANCER SPECIALISTS LLC | $3,180 | A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexam | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $4,047 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-08-26 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH | $13,556 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-08-05 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $125 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-07-22 | GENZYME CORPORATION | Innovative Clinical Research Institute, LLC | $8,338 | POC - Warm autoimmune hemolytic anemia | 2024 |
| 2024-05-02 | SANOFI US SERVICES INC. | Innovative Clinical Research Institute, LLC | $250 | Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Effica | 2024 |
| 2024-04-01 | Novartis Pharmaceuticals Corporation | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $594,622 | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2024 |
| 2024-02-15 | Janssen Research & Development, LLC | TOI CLINICAL RESEARCH | $26,617 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic L | 2024 |
| 2024-02-08 | SANOFI US SERVICES INC. | Innovative Clinical Research Instit Llc | $250 | Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Effica | 2024 |
| 2024-01-12 | E.R. Squibb & Sons, L.L.C. | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $46,760 | Phase III RRMM: 480Kd vs Kd (SUCCESSOR 2) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC | 2024 |
| 2023-12-18 | E.R. Squibb & Sons, L.L.C. | THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION | $4,550 | Phase III RRMM: 480Kd vs Kd (SUCCESSOR 2) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC | 2023 |
| 2023-12-05 | Karyopharm Therapeutics Inc. | TOI CLINICAL RESEARCH | $3,000 | A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE | 2023 |
| 2023-12-05 | Karyopharm Therapeutics Inc. | TOI CLINICAL RESEARCH | $1,500 | A phase 2, randomized, open-label, multicenter study of Selinexor or Physicians choice in patients with myelofibrosis | 2023 |
| 2023-12-05 | Karyopharm Therapeutics Inc. | TOI CLINICAL RESEARCH | $1,500 | A phase 2, randomized, open-label, multicenter study of Selinexor or Physicians choice in patients with myelofibrosis | 2023 |
| 2023-10-27 | SANOFI US SERVICES INC. | INNOVATIVE CLINICAL RESEARCH INSTITUTE LLC | $1,965 | Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Effica | 2023 |
| 2023-08-24 | Incyte Corporation | Innovative Clinical Research Institute | $1,250 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasi | 2023 |
| 2023-08-03 | SANOFI US SERVICES INC. | INNOVATIVE CLINICAL RESEARCH INSTITUTE LLC | $5,806 | Ph3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open Label Extension to Evaluate the Effica | 2023 |
| 2023-07-12 | E.R. Squibb & Sons, L.L.C. | INNOVATIVE CLINICAL RESEARCH | $11,800 | Phase III RRMM: 480Kd vs Kd (SUCCESSOR 2) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Downey, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Downey, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 110,939 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 114,355 | 10,014,009 | 39,538,223 |
| Median age B01002 | 37.7 | 38.2 | 37.9 |
| Under 18 B01001 | 21.3% | 20.6% | 22.0% |
| 65 and over B01001 | 14.2% | 15.2% | 15.7% |
| Households B11001 | 34,876 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 32.2% | 33.4% | 27.0% |
| Median household income B19013 | $90,699 | $90,112 | $99,122 |
| Median family income B19113 | $97,325 | $101,573 | $113,346 |
| Per capita income B19301 | $38,523 | $45,792 | $49,513 |
| Poverty rate B17001 | 9.0% | 13.7% | 12.0% |
| Unemployment rate B23025 | 5.8% | 7.3% | 6.6% |
| Civilian labor force B23025 | 59,357 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 31.0 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 26.1% | 36.0% | 37.1% |
| Housing units B25001 | 35,919 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 51.1% | 45.9% | 55.9% |
| Renters B25003 | 48.9% | 54.1% | 44.1% |
| Median home value B25077 | $796,600 | $834,200 | $734,700 |
| Median gross rent B25064 | $1,937 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 11.8% | 24.7% | 33.8% |
| Black B03002 | 3.4% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 75.3% | 48.4% | 40.2% |
| Asian B03002 | 7.3% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Downey, CA.
Comments